April 22 next meeting of the Transparency Council.
The agenda includes:
1 Prepare a position on the reimbursement of the medicinal product Lupkynis (voclosporinum) in the entire range of registered indications and indications.
2 Prepare a position paper on the reimbursement of the medicinal product Dupixent (dupilumabum) under the drug program "Treatment of patients with atopic dermatitis (ICD-10: L20)".
3...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
